This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Unmet Need in Multiple MyelomaMode of ActionAboutMagentisMM-3 Study OverviewMagnetisMM-3 Study Design and Efficacy OutcomesMagnetisMM-3 Study Safety ProfileMagnetisMM-3 StudySafetyDosingMaterialsVideosSupport & Resources

The content of this website has been produced in line with the ELREXFIO®▼ (elranatamab) Summary of Product Characteristics for Great Britain and Northern Ireland. For ELREXFIO®▼ (elranatamab) Prescribing Information for Great Britain and Northern Ireland click here.

ELREXFIO® is a humanised BCMA-CD3-directed bispecifc antibody that activates a tumour-specific immune response1-5

ELREXFIO® activates T cells, leading to the release of pro-inflammatory cytokines and subsequent MM cell lysis1-5

Target binding

T-cell activation

Tumor cell lysis

Binding of ELREXFIO® to BCMA on tumour cells and CD3 on T cells is independent of native T cell receptor (TCR) specificity or reliance on major histocompability (MHC) Class 1 molecules1

Cytotoxic T cells are recruited to tumour cells and form a cytolytic synapse, generating a robust T-cell response that is MHC-independent, which may contribute to the ability to overcome tumour escape mechanisms2-5

Cytolytic enzymes such as granzyme B and perforin are released, leading to tumor cell killing.5

ELREXFIO® is structurally designed to:

Confer tumour specificity

Promote stability

Dampen immunogenicity

Confer tumour specificity with an affinity for BCMA over CD36,7
Preferential binding to BCMA over CD3 promotes tumour specificity over T-cell activation.

Promote stability using a fully human immunoglobulin G (IgG) backbone8,9
Fully human IgG antibody design promotes stability and can prolong circulating half-life.

Dampen immunogenicity with modifications to inhibit fragment crystallisable receptor (FcR) engagement*8,10
Preclinical studies indicate that reduced FcR binding may minimise activation of immune effector cells.

Read more on BCMA as a target

BCMA is a tumour-associated antigen that is universally present on myeloma cells2,3

BCMA is selectively expressed on plasma cells and overexpressed on myeloma cells, with near ubiquitous expression across the multiple myeloma population. It is minimally expressed on haematopoetic stem cells and non-haematopoetic tissue.2 

BCMA expression and activation may contribute to multiple myeloma disease progression, promoting tumour cell survival and proliferation.2,11


Increased levels of BCMA on myeloma cells may enhance expression of immunoregulatory genes such as Interleukin (IL)-10 and programmed death ligand 1 (PD-L1), leading to immunosuppression. Additionally, increased levels of BCMA on plasmacytoid dendritic cells (PDCs) may promote survival and development of drug resistance in myeloma cells.11,12
References*Preclinical studies demonstrate that modification of the Fc region minimises binding and activation of immune effector cells, potentially minimising off-target toxicity.9,10
BCMA: B-cell maturation antigen; CD3: cluster of differentiation 3; CD38: cluster of differentiation 38; Fc: fragment crystallisable; FcR: fragment crystallisable receptor; IgG: immunoglobulin G; IL: interleukin; MHC: major histocompatibility complex; pDCs: plasmacytoid dendritic cells; PD-L1: programmed death-ligand 1; TCR: T-cell receptor.References:ELREXFIO® Summary of Product Characteristics. Click here for Great Britain. Click here for Northern Ireland.Shah N, et al. Leukaemia. 2020;34:985-1005.  Nadeem O, et al. Immunotargets Ther. 2020;9:201-215.  Caraccio C, et al. Front Immunol. 2020;11:501.Abramson HN. Int J Mol Sci. 2020;21:5192.Cho SF, et al. Front Immunol. 2018;9:1821.  Haber L, et al. Sci Rep. 2021;11:14397. Lejuene M, et al. Front Immunol. 2020;11:762.Ma H, et al. Biochimie. 2020;177:213-225. Saunders KO. Front Immunol. 2019;10:1296. Tai YT and Anderson KC. Immunotherapy. 2015;7:1187-1199. Tai YT, et al. Blood. 2016;127:3225-3236.   
MagnetisMM-3 study design and efficacyStudy design and efficacy data from the BCMA-directed therapy-naïve cohort of the Phase 2
MagnetisMM-3 study (n=123)
Read moreLoading
MagnetisMM-3 safety Safety profile of ELREXFIO® in BCMA-directed therapy-naïve patients in the Phase 2 MagnetisMM-3 study (n=183) Read moreLoading
PP-L1A-GBR-0021. March 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​